| 0.4284 0.002 (0.45%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.62 | 1-year : | 0.75 |
| Resists | First : | 0.53 | Second : | 0.64 |
| Pivot price | 0.44  |
|||
| Supports | First : | 0.36 | Second : | 0.29 |
| MAs | MA(5) : | 0.41  |
MA(20) : | 0.48 |
| MA(100) : | 0.71 |
MA(250) : | 0.87 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 23.3 |
D(3) : | 20.7 |
| RSI | RSI(14): 36.8 |
|||
| 52-week | High : | 3.14 | Low : | 0.36 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CVKD ] has closed above bottom band by 42.8%. Bollinger Bands are 45.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.44 - 0.44 | 0.44 - 0.44 |
| Low: | 0.42 - 0.42 | 0.42 - 0.42 |
| Close: | 0.43 - 0.43 | 0.43 - 0.43 |
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Sat, 20 Apr 2024
Favourable Signals For Cadrenal Therapeutics: Numerous Insiders Acquired Stock - Yahoo Finance UK
Tue, 09 Apr 2024
CVKD's price-to-free cash flow ratio: How it affects investment decisions – US Post News - US Post News
Tue, 12 Mar 2024
A New Cause for Concern: Cadrenal Therapeutics, Inc. Adds a New Natural and Human Disruptions Risk - TipRanks.com - TipRanks
Tue, 30 Jan 2024
Here's Why We're Not Too Worried About Cadrenal Therapeutics' (NASDAQ:CVKD) Cash Burn Situation - Yahoo Finance
Mon, 18 Dec 2023
Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day ... - Markets Insider
Wed, 12 Jul 2023
Cadrenal Therapeutics Announces $7.5 Million Private Placement Priced At-the-Market under Nasdaq Rules - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 16 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 46.7 (%) |
| Held by Institutions | 3.4 (%) |
| Shares Short | 42 (K) |
| Shares Short P.Month | 7 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.58 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -102.7 % |
| Return on Equity (ttm) | -780.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.48 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0.72 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.95 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|